Recent Settlement in Promega/Genovis Case Maintains Continued Offering of Promega IdeS/IdeZ Proteases

MADISON, Wis.--()--A recent settlement between Promega Corporation and Genovis AB maintains full freedom for the continued offering of Promega’s IdeS and IdeZ Proteases for markets worldwide. In November of 2014, Genovis and Hansa Medical AB filed a patent infringement suit in the U.S. While the details of the settlement are confidential, it allows for continued manufacture, sale and support of IdeS and IdeZ by Promega.

These products are used by scientists worldwide for a host of applications including early stage characterization of potential therapeutic antibodies that may someday be important for treating different diseases. The settlement allows that work to continue without interruption.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Contacts

Promega Corporation
Penny Patterson
Sr. Director, Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Release Summary

A recent settlement between Promega Corporation and Genovis AB maintains full freedom for the continued offering of Promega’s IdeS and IdeZ Proteases for markets worldwide.

Contacts

Promega Corporation
Penny Patterson
Sr. Director, Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com